Sally is currently Director of Research Services and Business Development at Queen Mary University of London and Barts Health NHS Trust. She is responsible for supporting research across the University and the Trust with teams in grants and finance, clinical trials research governance and compliance, clinical research facilities and business development.

Sally gained a first class honours degree in biochemistry at the University of St Andrews. She then spent a year at Emory University in Atlanta, USA as an RT (Bobby) Jones Scholar. From there she undertook a PhD in immunology at Bristol University. Following a subsequent post-doc at Bristol, Sally worked for the pharmaceutical company, Sandoz (now Novartis) in Basel, Switzerland undertaking diabetes resarch.

Sally returned to the UK to join Cancer Research UK as Assistant Director of Drug Development, responsible for the preclinical development of their portfolio of drug development candidates. She then progressed to be Director of Drug Development with oversight for the whole early drug development programme. While at CRUK, Sally and her team took over 50 potential novel anti-cancer drugs into clinical trials in patients with several making it to market including temozolomide (Temodal®) for certain types of brain cancer and abiraterone (Zytiga®) for advanced prostate cancer.

Sally changed roles in CRUK and became Director of Centres when she was responsible for establishing CRUK’s network of Cancer Centres across the country. These are partnerships between university and trust with an agreed joint strategy for cancer research. She was also responsible for leading the Experimental Cancer Medicine Centre network on behalf of CRUK and the four devolved UK Departments of Health.

While at CRUK Sally was a Board Director at Infermed a small company involved in health related software and on the Board of Governors of the Royal Marsden Hospital.

She then moved to become Director of Operations in the Department of Surgery and Cancer at Imperial College London where she was responsible for the establishment of the MRC-NIHR National Phoenome Centre. From there Sally moved to her current role at QMUL and Barts Health.

Back to our trustees